Abstract:Abstract Background: Mutations in the genes encoding isocitrate dehydrogenase (IDH1 and IDH2) are frequently detected in various cancers, including acute myeloid leukemia (~20%) and glioma (up to ~80%). They commonly involve a single amino acid substitution at codon R132 in IDH1, and R140 or R172 in IDH2 and are important for diagnosis and prognosis as well as therapeutic decisions. With advancements in molecular diagnostics and precision therapy, IDH inhibitors such as ivosidenib, vorasidenib and enasidenib are now mainstay in management of patients with a susceptible mutation. Methods: The IdyllaTM IDH1-2 Mutation Assay Kit (RUO) is a fully automated qPCR assay for the qualitative detection of 15 common mutations in IDH1 (R132C/H/G/S/L) and IDH2 (R140Q/L/G/W, R172K/M/G/W/S) at codon level. The assay consists of a ready-for-use IdyllaTM DNA Cartridge and an assay specific IdyllaTM Vial. It runs on the IdyllaTM Platform and covers the entire process from sample to result including specimen processing, real-time PCR amplification, detection, data analysis, and result reporting, within 100 minutes.Five clinical sites in US and Europe participated in an early access program to evaluate performance of the assay and establish a final classification algorithm by testing a total of 241 specimens, including FFPE, human whole blood and bone marrow samples, and extracted DNA from these sample types. Reference results were obtained using a range of established methods with different mutations in scope, such as Sanger sequencing, immunohistochemistry, NGS and qPCR. Results: Of 241 Cartridges, one invalid result was obtained, while 13 results were flagged as having low DNA input. Compared to available reference methods, overall concordance was 98.3% (235/239), 100% (140/140) and 99.6% (230/231) for IDH1 R132, IDH2 R140 and R172, respectively (see table). Conclusion: The IdyllaTM IDH1-2 Mutation Assay Kit demonstrates a high concordance with established reference methods across a range of different specimen types. Reference method(s) PPA (%) NPA (%) OPA (%) MUT WT Total IdyllaTM IDH1-2 Mutation Assay Kit IDH1_R132x 111 3 114 99.1 97.6 98.3 WT 1 124 125 Total 112 127 239 IDH2_R140x 10 0 10 100.0 100.0 100.0 WT 0 130 130 Total 10 130 140 IDH2_R172x 25 0 25 96.2 100.0 99.6 WT 1 205 206 Total 26 205 231 Total 148 462 610 Citation Format: Bram De Craene, Katrien Trappeniers, Ana Marcelino, Lee Robertson, Phillippe Taniere, Jo Van Dorpe, Malaïka Van der Linden, Maria Arcila, Khedoudja Nafa, Jochen K. Lennerz, Richard Craig Carson, Richard D. Ledding, Sofie Metsu. The IdyllaTM IDH1-2 Mutation Assay Kit: A tool for mutation detection in IDH1 and IDH2 genes [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 556.

Evaluation of the rapid Idylla IDH1-2 mutation assay in FFPE glioma samples

Abstract 556: The IdyllaTM IDH1-2 Mutation Assay Kit: A tool for mutation detection in IDH1 and IDH2 genes

Clinical utility of a blood based assay for the detection of IDH1.R132H-mutant gliomas

Comparative study of IDH1 mutations in gliomas by high resolution melting analysis, immunohistochemistry and direct DNA sequencing

Rapid Diagnosis of IDH1-mutated Gliomas by 2-HG Detection with Gas Chromatography Mass Spectrometry.

Rapid extraction-free detection of the R132H isocitrate dehydrogenase mutation in glioma using colorimetric peptide nucleic acid-loop mediated isothermal amplification (CPNA-LAMP)

Predicting IDH mutation status as well as Ki-67 and p53 expression in high-grade gliomas using amide proton transfer-weighted and arterial spin labeling MRI

Microfluidics for rapid detection of isocitrate dehydrogenase 1 mutation for intraoperative application.

Detection of the IDH1/2 Gene Mutations in Tumor Samples with Low-Abundance Mutant Allele

Resolving Discrepancies in Idylla BRAF Mutational Assay Results Using Targeted Next-Generation Sequencing

IDH1 Mutation Detection by Droplet Digital PCR in Glioma.

Digital Droplet PCR is a Specific and Sensitive Tool for Detecting IDH2 Mutations in Acute Myeloid LeuKemia Patients

Development of a Hydrogen Peroxide Fluorescent Probe for the Rapid Discrimination of IDH1 Mutant Gliomas from the Wild-type

Application of IdyllaTM System for Rapid Evaluation of EGFR Mutation Status in Formalin-Fixed and Paraffin-Embedded Samples of Non-Small Cell Lung Cancer.

Evaluation of the Idylla™ EGFR Mutation Test on Formalin-Fixed, Paraffin-Embedded Tissue of Human Lung Cancer.

Rapid detection of IDH mutations in gliomas by intraoperative mass spectrometry

Detection of IDH mutation in glioma by desorption electrospray ionization (DESI) tandem mass spectrometry

Immu-13. Trans-Species Study Of Idh-Mutant Replication-Repair Deficient High-Grade Gliomas (Rrd-Hgg) And Response To Combined Targeted And Immunotherapy: An Irrdc Study

Preliminary Establishment of High Resolution Melting Analysis for Detecting IDH1 Gene Mutations in Gliomas

Rapid Determination of Isocitrate Dehydrogenase Mutation Status of Human Gliomas by Extraction Nanoelectrospray Using a Miniature Mass Spectrometer

Detection of IDH1 Mutations in Plasma Using BEAMing Technology in Patients with Gliomas